Metformina Tevagen

Metformin Hydrochloride, the active ingredient in Metformina Tevagen, is a Biguanide presented as a 500 mg tablet for oral use. It lowers elevated blood glucose in adults with type 2 diabetes mellitus by reducing hepatic glucose output and improving peripheral insulin sensitivity.

GNH USA supplies Metformina Tevagen as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory conformity and timely delivery.

Metformina Tevagen (metformin hydrochloride) is used in the management of disorders related to impaired glucose regulation.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): helps delay progression to type 2 diabetes when combined with lifestyle modification. - Metabolic syndrome: contributes to weight management and insulin sensitivity as part of a comprehensive treatment plan.

Metformina Tevagen may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhea: often mild to moderate and transient. - Metallic taste in the mouth. - Weight loss: modest reduction observed in many patients. - Vitamin B12 deficiency: may develop with long‑term therapy.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: elevated transaminases in susceptible individuals. - Pancreatitis: infrequent inflammatory reaction of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Metformina Tevagen, clinicians should observe several safety considerations to minimize risk.

- Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Hepatic function: avoid use in patients with severe liver disease. - Contraindication in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m². - Monitor blood glucose: adjust dose to avoid hypoglycemia, especially when combined with insulin or sulfonylureas. - Avoid excessive alcohol: increases risk of lactic acidosis. - Store at below 25°C: keep in the original packaging, protect from moisture.

Metformina Tevagen can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; pause metformin around the procedure. - Cimetidine: can increase metformin plasma concentrations, raising toxicity risk. - Certain diuretics (e.g., furosemide) in renal impairment: heighten the chance of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - ACE inhibitors or ARBs: can affect renal function; monitor creatinine and electrolytes. - Alcohol: potentiates lactic acidosis risk, especially with high intake.